Prospect: information for the user
Gabapentin Aurovitas 600 mg film-coated tablets
Read this prospect carefully before starting to take this medicine, as it contains important information for you.
6. Contents of the pack and additional information
The active ingredient of Gabapentina Aurovitas is gabapentin.
Gabapentin is used to treat:
Do not take Gabapentina Aurovitas:
Warnings and precautions
Consult your doctor or pharmacist before starting to take gabapentin:
Dependence
Some people may develop dependence (need to continue taking the medicine) on gabapentin. They may experience withdrawal symptoms when they stop taking gabapentin (see section 3, "How to take Gabapentina Aurovitas" and "If you interrupt treatment with Gabapentina Aurovitas"). If you are concerned about developing dependence on gabapentin, it is essential to consult your doctor.
If you experience any of the following signs while taking gabapentin, it may be indicative of dependence.
- You feel the need to take the medicine for a longer time than prescribed.
- You feel the need to take a higher dose than recommended.
- You are taking the medicine for reasons other than your prescription.
- You have tried several times to stop taking the medicine or control how you take it, without success.
- When you stop taking the medicine, you feel unwell and feel better when you take it again.
If you notice any of the above, talk to your doctor to decide on the best course of treatment for you, including when it is appropriate to stop treatment and how to do it safely.
A small number of people treated with antiepileptic drugs such as gabapentin have had thoughts of harming themselves or committing suicide. If you ever have these thoughts, contact your doctor immediately.
Important information about potentially serious adverse reactions
Severe skin reactions associated with the use of gabapentin have been reported, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS). Stop taking gabapentin and seek medical attention immediately if you notice any of the symptoms related to these severe skin reactions described in section 4.
Read the description of severe symptoms in section 4 of this leaflet“Contact your doctor immediately ifyou experience any of the following symptoms after taking this medicine, as they may be serious”.
Muscle weakness, sensitivity, or pain, and especially if you feel unwell or have a fever, could be due to an abnormal breakdown of muscle fibers that may lead to kidney problems and put your life at risk. You may also experience urine discoloration and changes in blood test results (significant increase in creatine phosphokinase in the blood). If you experience any of these signs or symptoms, please contact your doctor immediately.
Other medicines and Gabapentina Aurovitas
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medicine.Especially, inform your doctor (or pharmacist) if you are taking or have taken recently any medicine for seizures, sleep disorders, depression, anxiety, or any other neurological or psychiatric problem.
Medicines containing opioids such as morphine:
If you are taking any medicine containing opioids (such as morphine), inform your doctor or pharmacist, as opioids may increase the effect of gabapentin. Additionally, the combination of gabapentin with opioids may cause drowsiness, sedation, decreased breathing, or death.
Antacids for indigestion:
If you take gabapentin at the same time as antacids containing aluminum or magnesium, the absorption of gabapentin in the stomach may be reduced. It is recommended that gabapentin be taken at least two hours after taking an antacid.
Gabapentin:
Taking Gabapentina Aurovitas with food, drinks, and alcohol
Gabapentin can be taken with or without food.
Pregnancy, breastfeeding, and fertility
Pregnancy
Gabapentin can be used during the first trimester of pregnancy if necessary.
If you plan to become pregnant or are pregnant or think you may be pregnant, consult your doctor immediately.
If you become pregnant and have epilepsy, it is essential not to stop taking your medicine without first consulting your doctor, as this may worsen your condition. Worsening of your epilepsy may put both you and your unborn baby at risk.
In a study that reviewed data from women in Nordic countries who took gabapentin in the first 3 months of pregnancy, there was no increased risk of birth defects or problems with brain function development (neurodevelopmental disorders). However, babies of women who took gabapentin during pregnancy had a higher risk of low birth weight and premature birth.
Gabapentin taken during pregnancy may cause withdrawal symptoms in newborns. This risk may be higher when gabapentin is taken concomitantly with opioid analgesics (pain medications).
Contact your doctor immediately if you become pregnant, think you may be pregnant, or plan to become pregnant while taking gabapentin. Do not stop taking this medicine abruptly, as this may cause an anticipation of seizures, which could have serious consequences for both you and your baby.
Breastfeeding
Gabapentin, the active ingredient of gabapentin, passes into breast milk. It is not recommended to breastfeed while taking gabapentin, as its effect on the baby is unknown.
Fertility
No effects on fertility were found in animal studies.
Driving and operating machinery
Gabapentin may cause dizziness, drowsiness, and fatigue. Do not drive, operate heavy machinery, or engage in other potentially hazardous activities until you know if this medicine affects your ability to perform these activities.
Your doctor will determine the suitable dose for you.
Epilepsy, the recommended dose is:
Adults and adolescents:
Take the number of tablets as indicated by your doctor. Normally, your doctor will gradually increase your dose. The initial dose will generally be between 300 mg and 900 mg per day. From there, the dose can be increased as indicated by your doctor up to a maximum dose of 3,600 mg per day, and the total daily dose will be divided into three equal doses, for example, one in the morning, one in the middle of the day, and one at night.
Children 6 years or older:
Your doctor will decide on the dose to be administered to your child, based on the child's weight. The treatment will begin with a low initial dose that will be gradually increased over a period of approximately three days. The normal dose for controlling epilepsy is 25-35 mg per kg per day. The dose is normally administered by taking the tablets, divided into three equal doses per day, normally one in the morning, one in the middle of the day, and one at night.
Gabapentin is not recommended for use in children under 6 years of age.
Peripheral neuropathic pain, the recommended dose is:
Adults:
Take the number of tablets as indicated by your doctor. Normally, your doctor will gradually increase your dose. The initial dose will generally be between 300 mg and 900 mg per day. From there, the dose can be increased up to a maximum dose of 3,600 mg per day, and divided into three equal doses, for example, one in the morning, one in the middle of the day, and one at night.
If you have kidney problems or are being hemodialyzed
Your doctor may prescribe a different dosing regimen and/or doses if you have kidney problems or are being hemodialyzed.
If you are an elderly patient (over 65 years of age)
You should take gabapentin normally except if you have kidney problems. Your doctor may prescribe a different dosing regimen or doses if you have kidney problems.If you consider that the effect of gabapentin is too strong or too weak, inform your doctor or pharmacist as soon as possible.
Method of administration
Gabapentin is administered orally. Always swallow the tablets with a sufficient amount of water.
The tablet can be divided into two equal doses.
Continue taking gabapentin until your doctor tells you to stop.
If you take more Gabapentina Aurovitas than you should
Doses higher than recommended may cause an increase in adverse effects, including loss of consciousness, dizziness, double vision, slurred speech, numbness, and diarrhea. In case of overdose or accidental ingestion, consult your doctor, pharmacist, or call the Toxicological Information Service (phone 915620420), indicating the medication and the amount ingested. Bring with you any remaining tablets, along with the packaging and label so that the hospital can easily identify the medication you have taken.
If you forgot to take Gabapentina Aurovitas
If you forgot to take a dose, take it as soon as you remember, unless it is time for the next dose. Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with Gabapentina Aurovitas
Do not stop taking gabapentin suddenly. If you want to stop taking gabapentin, talk to your doctor first. Your doctor will indicate how to proceed.If you are going to stop treatment, this should be done gradually over a minimum of one week.You should know that you may experience certain adverse effects, called withdrawal syndrome, after interrupting a short or long-term treatment with gabapentin. These include seizures, anxiety, difficulty sleeping, feeling unwell (nausea), pain, sweating, tremors, headache, depression, abnormal sensation, dizziness, and general feeling of unwellness. These effects usually occur within the first 48 hours after interrupting treatment with gabapentin. If you experience this withdrawal syndrome, contact your doctor.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication may have adverse effects, although not everyone will experience them.
Stop taking gabapentin and seek medical attention immediately if you notice any of the following symptoms:
Contact your doctor immediately if you experience any of the following symptoms after taking this medication, as they may be serious:
Contact your doctor immediately if you have any of the following symptoms:
These symptoms may be the first signs of a severe reaction. Your doctor should examine you to decide if you should continue taking gabapentin.
If you are on hemodialysis, inform your doctor if you start feeling muscle pain and/or weakness.
Other adverse effects include:
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
In addition, in clinical trials in children, frequent adverse effects reported included aggressive behavior and spasmodic movements.
Rare (may affect up to 1 in 1,000 people):
Adverse effects reported after gabapentin's commercialization:
You should know that you may experience certain adverse effects, called withdrawal syndrome, after interrupting a short- or long-term treatment with gabapentin (see "If you stop taking gabapentin").
Reporting adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Vigilance of Medicinal Products for Human Use:https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after CAD.The expiration date is the last day of the month indicated.
Do not store at a temperature above 25°C.
Medications should not be disposed of through drains or in the trash. Dispose of packaging and medications you no longer need at the SIGRE collection point at the pharmacy.Ask your pharmacist how to dispose of packaging and medications you no longer need. This will help protect the environment.
Composition of Gabapentina Aurovitas
Each film-coated tablet contains 600 mg of gabapentin.
Coating:Hydroxypropylcellulose, talc.
Appearance of the product and content of the container
Film-coated tablet.
Gabapentina Aurovitas 600 mg film-coated tablets EFG are film-coated tablets, white in color, eliptical in shape, biconvex, with a deep groove on both faces, with the letter “D” and the number “24” printed on one face on both sides of the groove and not printed on the other face.
Gabapentina Aurovitas 600 mg film-coated tablets EFG is available in a polyamide/aluminum/PVC blister with an aluminum foil containing 20, 60, and 90 film-coated tablets.
Only some container sizes may be commercially available.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization:
Aurovitas Spain, S.A.U.
Avda. de Burgos, 16-D
28036 Madrid
Spain
Responsible for manufacturing:
APL Swift Services (Malta) Limited
HF26, Hal Far Industrial Estate, Hal Far,
Birzebbugia, BBG 3000
Malta
This medicine is authorized in the member states of the European Economic Area with the following names:
Spain:Gabapentina Aurovitas 600 mg film-coated tablets EFG
Last review date of this leaflet: January 2024
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/)
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.